PereiraJ, PhanT: Management of bleeding in patients with advanced cancer. Oncologist, 2004; 9:561–570.
2.
SmithLB, CoolingL, DavenportR: How do I allocate blood products at the end of life? An ethical analysis with suggested guidelines. Transfusion, 2013; 53:696–700.
3.
NeeR, DoppenschmidtD, DonovanDJ, AndrewsTC: Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol, 1999; 83:286–288.
4.
ShieldsRC, McBaneRD, KuiperJD, et al.: Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc, 2011; 76:260–266.
5.
PatelRJ, WittDM, SaseenJJ, et al.: Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy, 2000; 20:1159–1166.
6.
WhitlingAM, BusseyHI, LyonsRM: Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med, 1998; 158:2136–2140.
7.
LassauniereJM, BertolinoM, HunaultM, et al.: Platelet transfusions in advanced hematological malignancies: A position paper. J Palliat Care, 1996; 12:38–41.
8.
KliebH, GilbertM: How to manage spontaneous gingival hemorrhage. J Can Dent Assoc, 2014; 80:e54.
9.
FoleySJ, SolomonLZ, et al.: A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol, 2000; 163:496–498.
D'AmicoG, PietrosiG, TarantinoI, PagliaroL: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A Cochrane meta-analysis. Gastroenterology, 2003; 124:1277–1291.
13.
LambertsSW, van der LelyAJ, de HerderWW, HoflandLJ: Octreotide. N Engl J Med, 1996; 334:246–254.
14.
FargoMW, LatimerKM: Evaluation and management of common anorectal conditions. Am Fam Physician, 2012; 85:624–630.
